The current book series discusses the advancement in effective cancer therapy and deals with the developments of new drugs and new patented targets, agents and synthetic compounds. The following areas have been highlighted in this volume:
- Recent patent literature reveals the role of estrogen as endocrine disruptor through inhibition of the AF1 Domain of liganded and unliganded Estrogen Receptors (ERs).
- Natural and potent synthetic phenazines patent derivatives with substituent groups i.e. alkyl, amide, carboxylic acid, aldehyde, and pyrano groups show potent anticancer activities.
- The potential role of ShcA proteins in stimulating metastasis and advancement of cancer will offer the new tools for cancer therapy. New approaches and challenges for cancer stem cell aiming at cancer therapy is included in this volume.
- The anti-tumor activity of mono Bcl-2 inhibitors and Bcl-2 inhibitors in combination with rapologs will be a novel beneficial invention for the cure of advanced Renal Cell Carcinoma (RCC) as well as other cancer.
The diversity of research topics published in this series will be valuable for cancer researchers, clinicians and cancer professionals aiming to develop new anti-cancer targets and patents for the treatment of various cancers.
About The Editors:
Dr. Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1150 international publications in several fields of organic chemistry including 775 research publications, 43 international patents, 70 chapters in books and 254 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world's leading encyclopaedic series of volumes on natural products "Studies in Natural Product Chemistry" 60 volumes of which have been published under his Editorship by Elsevier during the last two decades.
Dr. Khurshid Zaman completed her Ph.D. in Organic Chemistry from H.E.J. Institute of Chemistry, Karachi, Pakistan. Some research work on trace element analysis and Liver regeneration was carried out from Lund University Sweden during her Ph.D. She has done Post Doc. Research from Hamdard University in collaboration with H.E.J. Institute of Chemistry, Karachi, Pakistan and from Geneva, Switzerland in the area of tissue culture. She has published research papers, reviews and edited several book series volumes. She was the Editor of Pakistan Journal of Scientific Research. Dr. Zaman is currently serving as the Executive Editor of Patent Journals and Book series at Bentham Science Publishers. She is also a member of WAME and UNIDO Assessor in Laboratory Accreditation ISO/IEC 17025.
Cancer therapy, Anti-cancer research, Phenazines, Anticancer activities, Mono Bcl-2 inhibitors, AF1 Domain, ShcA proteins, Patented targets